博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书

Core Viewpoint - 博瑞医药's subsidiary, 博瑞制药, has received approval from the National Medical Products Administration for clinical trials of BGM1812 injection for overweight or obesity treatment [1] Group 1: Company Developments - 博瑞制药 has been granted a clinical trial approval for BGM1812 injection, a new long-acting Amylin analog designed to aid in weight management [1] - BGM1812 injection is noted for its good molecular activity and pharmaceutical stability, indicating potential effectiveness in clinical applications [1] Group 2: Product Mechanism - Amylin, a hormone composed of 37 amino acids, is released by pancreatic β-cells alongside insulin and plays a role in appetite regulation [1] - The mechanism of Amylin includes activating brain pathways that suppress appetite, delaying gastric emptying, and inhibiting glucagon secretion, contributing to weight loss [1]